Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)

2015-05-28 22:37:25 | BioPortfolio

Published on BioPortfolio: 2015-05-28T22:37:25-0400

Clinical Trials [6 Associated Clinical Trials listed on BioPortfolio]

Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia

Frontotemporal lobar degeneration(FTLD) is a common cause of early-onset dementia. FTLD is characterized multiple behavioral symptoms including mental rigidity, irritability, emotional bl...

Multidisciplinary and Personalized Care of Behavioral Disorders in Frontotemporal Lobar Degeneration.

Fronto-Temporal Lobar Degeneration (FTLD) is neurodegenerative disease which comes in three clinical categories: Fronto-Temporal Dementia behavioral variant (FTD), Primary Progressive Apha...

A 52 Week Open Label Trial of Memantine for Frontotemporal Lobar Degeneration

This is a 52-week, multicenter, open label trial of memantine (Namenda) for frontotemporal lobar degeneration (FTLD). The goal is to determine the safety and tolerability of this FDA-appr...

Diagnosing Frontotemporal Lobar Degeneration

To establish diagnostic tools to make an accurate clinical and pathological diagnosis of patients with clinical FTLD syndromes

Davunetide (AL-108) in Predicted Tauopathies - Pilot Study

The primary objective of the study is to obtain preliminary safety and tolerability data with davunetide (NAP, AL-108) in patients with a tauopathy (frontotemporal lobar degeneration [FTLD...

PubMed Articles [16 Associated PubMed Articles listed on BioPortfolio]

Clinical features of the behavioural variant of frontotemporal dementia that are useful for predicting underlying pathological subtypes of frontotemporal lobar degeneration.

The behavioural variant of frontotemporal dementia (bvFTD) is the most common phenotype of frontotemporal lobar degeneration (FTLD). FTLD is divided into three main pathological subtypes: tau-positive...

Prevalence of immunological diseases in a Finnish frontotemporal lobar degeneration cohort with the C9orf72 repeat expansion carriers and non-carriers.

Recent studies have suggested a role for immune dysregulation behind the etiology of frontotemporal lobar degeneration (FTLD). Here, we have investigated the prevalence of immunological diseases in FT...

FTLD/ALS-linked TDP-43 mutations do not alter TDP-43's ability to self-regulate its expression in Drosophila.

TDP-43 is a major disease-causing protein in amyotrophic lateral sclerosis (ALS) and Frontotemporal Lobar Degeneration (FTLD). Today, more than 50 missense mutations in the TARDBP/TDP-43 gene have bee...

Genotype-phenotype links in frontotemporal lobar degeneration.

Frontotemporal lobar degeneration (FTLD) represents a group of neurodegenerative brain diseases with highly heterogeneous clinical, neuropathological and genetic characteristics. This high degree of h...

A Review: Mealtime Difficulties following Frontotemporal Lobar Degeneration.

Frontotemporal lobar degeneration (FTLD) can result in a decline in behavior, language, and motor function. Mealtime disturbances are a common and significant outcome of FTLD. Disturbances during meal...

Medical and Biotech [MESH] Definitions

Heterogeneous group of neurodegenerative disorders characterized by frontal and temporal lobe atrophy associated with neuronal loss, gliosis, and dementia. Patients exhibit progressive changes in social, behavioral, and/or language function. Multiple subtypes or forms are recognized based on presence or absence of TAU PROTEIN inclusions. FTLD includes three clinical syndromes: FRONTOTEMPORAL DEMENTIA, semantic dementia, and PRIMARY PROGRESSIVE NONFLUENT APHASIA.

More From BioPortfolio on "Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)"

Quick Search


Searches Linking to this Trial